Replimune, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS6
PHASE 3 / 2-32
RECRUITING3
READOUTS ≤12 MONTHS0
READOUT SLIPPED >6 MO80%
Delay Index: of 5 active trials registered more than a year ago, 4 have moved their primary completion (readout) date by more than 6 months since first registration (median +20.9 months). See all sponsors →
Open Replimune, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| CERPASS NCT04050436 |
P2 | Active, not recruiting | Cutaneous Squamous Cell Carcinoma; Advanced Cutaneous Squamous Cell Carcinoma | 231 | 2025-09 |
| RP2 NCT05733598 |
P2 | Recruiting | Hepatocellular Carcinoma; Biliary Tract Cancer | 60 | 2027-12-01 (+11 mo) |
| IGNYTE NCT03767348 |
P2 | Active, not recruiting | Non-Small Cell Lung Cancer (NSCLC); Microsatellite Instability-High (MSI-H) | 340 | 2028-06 (+79 mo) |
| ARTACUS NCT04349436 |
P1/2 | Active, not recruiting | Merkel Cell Carcinoma; Basal Cell Carcinoma | 69 | 2029-07 (+65 mo) |
| RP2 NCT06581406 |
P2/3 | Recruiting | Metastatic Uveal Melanoma | 280 | 2030-01 |
| Vusolimogene Oderparepvec NCT06264180 |
P3 | Recruiting | Advanced Melanoma | 400 | 2030-09-30 (+21 mo) |